Would Sunvozertinib Still Be Unable to Launch Commercially in the US Without AstraZeneca's Acquisition?

AstraZeneca announced on October 22, 2026 that sunvozertinib is officially launched in the United States, but the source did not state whether the acquisition was a precondition for commercialization. The drug treats previously treated EGFR exon 20 insertion-mutated NSCLC; the article says it is the only approved oral single-agent targeted therapy for such patients after platinum chemotherapy.